Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011

Routine periodic fasting can reduce risk of coronary heart disease

Fasting has long been associated with religious rituals, diets, and political protests. Now new evidence from cardiac researchers at the Intermountain Medical Center Heart Institute demonstrates that routine periodic fasting is also good for your health, and your heart.

4 Apr 2011

20-year data shows bariatric surgery to reduce risk of heart attack and stroke in diabetics

In the longest study of its kind, bariatric surgery has been shown to reduce the risk of heart attack and stroke in patients with diabetes. These results and other groundbreaking research were presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes, hosted by NewYork-Presbyterian Hospital and Weill Cornell Medical College.

31 Mar 2011

Low doses of estrogen, growth hormone can increase height in girls with Turner syndrome

Giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers a wealth of other benefits, say a team of researchers led by Thomas Jefferson University.

31 Mar 2011

HCG hormone therapy may benefit patients with intractable pain

Results from a small study of intractable pain patients being treated with the human chorionic gonadotropin (HCG) hormone reported that they had experienced pain free hours in the past month. These results were presented at a poster session at the American Academy of Pain Medicine's 27th Annual Meeting.

25 Mar 2011

City Of Hope opens new center for diabetes research and care

City of Hope has established a new Diabetes Research Center that will expand its pioneering investigations into diabetes, endocrinology and metabolic diseases, create an infrastructure to support translational research and enhance clinical care for diabetes and its related complications.

22 Mar 2011

Girls with medical conditions causing short stature go undiagnosed

Primary care doctors are less likely to refer short girls than short boys for diagnostic testing that can reveal underlying medical reasons for their short stature, according to a new study of an urban pediatric population in Philadelphia. Girls with medical conditions causing their short stature may go undiagnosed, or may be diagnosed later than boys, limiting timely treatment.

21 Mar 2011

New IAF study identifies ten states as 'diabetes hot spots'

A new study conducted by the Institute for Alternative Futures identified California, Texas, Florida, New York, Ohio, Illinois, Georgia, Pennsylvania, North Carolina and Michigan as "diabetes hot spots," where the burden of diabetes will be greatest in the next 15 years.

18 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Scientists discover how change in growth hormone activity leads to fatty liver disease

Scientists at the UCSF Cardiovascular Research Institute have discovered how a change in growth hormone activity in mice leads to fatty liver disease, a condition whose human counterpart is of rising concern worldwide.

2 Mar 2011

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.

From Novo Nordisk 23 Feb 2011

A special type of Dwarfism protects against cancer & diabetes: Study

Researchers have found that some individuals living in remote villages in Ecuador have a mutation that could throw light on human longevity and ways to increase it. These villagers, all dwarfs with heights less than three and a half feet, have a rare condition called Laron syndrome or Laron dwarfism.

20 Feb 2011

Researchers develop new DNA test for accurate detection of Turner syndrome in children

As a child grows, a short stature is not usually cause for concern, but it is often the only sign of a condition called Turner syndrome. Prevalent in girls, Turner syndrome is a genetic defect that short-circuits normal growth and leads to cardiac and renal problems. It is not commonly detected until age 10 or older when a youngster's unusually short height raises suspicions.

16 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011.

14 Feb 2011

First mobile application is now available for clinicians to diagnose bleeding disorders

Novo Nordisk announced today the availability of Coags Uncomplicated – the first mobile application to assist in the diagnosis of bleeding disorders – created in partnership with Craig Kessler, MD, Professor of Medicine and Pathology and Director of the Coagulation Laboratory, Georgetown University Hospital, Lombardi Comprehensive Cancer Center.

5 Feb 2011

Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX in Factor IX-depleted hemophilic mice.

3 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

New study reveals illicit HGH use among young American male weightlifters

A new study published in The American Journal on Addictions reveals that illicit use of HGH has become common among young American male weightlifters.

21 Jan 2011